<DOC>
	<DOCNO>NCT01356316</DOCNO>
	<brief_summary>Each potential subject screen start study determine eligibility participation . Just prior vaccination , 10 mL venous blood sample take eligible subject , baseline titration circulate anti-HA antibody . Immediately thereafter , subject receive one dose vaccine ( 0.5 mL ) intramuscular injection upper arm . Subjects ask stay site 30 minute post-vaccination observe immediate reaction . Subjects monitor adverse event study . At three week ( ±3 day ) vaccination , subject ask return site final collection blood sample .</brief_summary>
	<brief_title>Immunogenicity Safety Trivalent Inactivated Influenza Vaccine , Formulation 2010-2011 , Non-Elderly Adult Elderly Subjects</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Males nonpregnant female age ³ 18 year ; Willing able adhere visit schedule study requirement ; Subjects read sign studyspecific inform consent . Subject his/her family employ participated hospital ; Subjects receive influenza vaccine ( Trivalent and/or A ( H1N1 ) ) within previous 6 month ; History hypersensitivity egg egg protein similar pharmacological effect study medication ; Personal family history GuillainBarré Syndrome ; An acute febrile illness within 1 week prior vaccination ; Current upper respiratory illness ( URI ) , include common cold nasal congestion within 72 hour ; Patients influenzalike illness define presence fever ( temperature ≥38ºC ) least two follow four symptom : headache , muscle/joint ache pain ( e.g . myalgia/arthralgia ) , sore throat cough ; Female subject pregnant , lactate likely become pregnant study ; Women childbearing potential disagree use acceptable method contraception ( e.g. , hormonal contraceptive , IUD , barrier device abstinence ) throughout study . Treatment investigational drug device , participation clinical study , within 3 month consent ; Immunodeficiency , immunosuppressive household contact immunosuppression ; History wheeze bronchodilator use within 3 month prior study vaccine ; Receipt live virus vaccine within 1 month prior study vaccine expect receipt within 1 month study vaccination ; Receipt inactivate vaccine within 2 week prior study vaccination expect receipt within 1 month study vaccination ; Receipt blood product , include immunoglobulin prior 3 month ; Underlying condition investigator ' opinion may interfere evaluation vaccine ; Significant chronic illness inactivate influenza vaccine recommend commonly use .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>